



Cowen and Company Healthcare Conference: *Pfizer Oncology*

March 12, 2019

Andy Schmeltz,
*Global President & General
Manager, Pfizer Oncology*

Chris Boshoff, M.D., Ph.D.,
*Chief Development Officer, Oncology,
Pfizer Global Product Development*

Forward Looking Statements

This presentation may include forward-looking statements about, among other things, Pfizer's oncology in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, performance and potential benefits of Pfizer's oncology products and product candidates, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

Additional information regarding these factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and in our subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors that May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission (SEC) and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in this presentation speak only as of the original date of this presentation, and we undertake no obligation to update or revise any of these statements.



Continued Growth and Commitment to Oncology

> 1.2M

patients treated with
Pfizer medicines since 2006

31%

CAGR (compound annual
growth rate) in revenue
from 2013-2018

LARGEST

% of Pfizer investment in
R&D goes to Oncology

> 10K

patients participating in
ongoing Pfizer sponsored
clinical trials

Advancing Our Leadership

Today

18 approved cancer
medicines & biosimilars

2025

Up to **20** potential
approvals

A Focused Pfizer Oncology Vision and Strategy

Our Commitment to Changing the Lives of People Living with Cancer

1

Extend our leadership in
breast and prostate

IBRANCE™
palbociclib

Xtandi.
(enzalutamide)
capsules

2

Advance our portfolio
and deliver precision
immunotherapy approaches

Bosulif®
bosutinib tablets

BESPONSA®
inotuzumab ozogamicin intravenous injection


BAVENCIO®
avelumab 20 mg/mL

Inlyta.
axitinib 7mg and 5mg tablets

LORBRENA®
LORLATINIB | 5mg tablets


3

Lead a next wave of
innovation in immunotherapy
and targeted medicines




Strategic Approach to Developing Breakthroughs For Patients


TARGETING THE TUMOR




TARGETING THE TUMOR MICROENVIRONMENT




INNOVATIVE MODALITIES TO DRIVE POTENTIAL FUTURE THERAPIES



NCEs




mAbs



ADCs



Bi-Specifics



Vaccines



Pfizer Select NME & Programs

Early Development

NG-HER2
(Biologic)

Anti-PD1
IO (Biologic)

TGFβR1
(small molecule)

CDK2/4/6
(small molecule)

VBIR1
(Vaccine)

Cell Cycle

Therapeutic Vaccine

Immunotherapy

Antibody Drug Conjugate

Registration Intent Studies

Breast

IBRANCE
PENELOPE B

IBRANCE
PALLAS

IBRANCE
PATINA

TALZENNA
EMBRACA

TALZENNA
JAVELIN BRCA

Prostate

XTANDI
EMBARK

TALZENNA
TALAPRO 1

XTANDI + TALZENNA
TALAPRO 2

XTANDI
IMBASSADOR 250 PD-L1

XTANDI
KN-641 PD-1

XTANDI*
ARCHES

Hem., Renal, Lung & IO

DAURISMO
AML 1L

BAVENCIO
UCC 1L

INLYTA
RCC 1L

BAVENCIO
GASTRIC 1L

TALZENNA
JAVELIN PARP

BAVENCIO
HNSCC LA

LORBRENA
ALK NSCLC 1L



Combinations

Collaborations, non-Pfizer, non-Pfizer/Astellas sponsored study

* Positive data read-out

Q&A